|
Published by: PJB Publications USA Inc.
Published: Aug. 1, 2002 - 364 Pages
Table of Contents
1 Executive Summary
1.1 Scope and Objectives of the Report
1.2 Methodology
1.3 World Market for Pulmonary/Lung Pharmaceuticals
1.3.1 Market Size, Forecast, and Product Drivers
1.3.2 Market Share by Disease Area
1.3.3 Competitor Market Summary
2 Introduction
2.1 Definition of Pulmonary/Lung Diseases
2.2 Major Pulmonary/Lung Diseases: Description, Pathology, and Demographics
2.2.1 Asthma
2.2.2 COPD
2.2.3 Pulmonary Fibrosis and Sarcoidosis
2.2.4 Cystic Fibrosis
2.2.5 Primary Pulmonary Hypertension
3 Chronic Obstructive Pulmonary Disease
3.1 Overview
3.1.1 GOLD Stages of COPD
3.2 Risk factors
3.2.1 Genetic Risk Factors
3.2.2 Environmental Risk Factors
3.2.3 Airway Hyperresponsiveness
3.3 Incidence and Mortality
3.4 Treatments for COPD
3.4.1 Anticholinergic (Antimuscarinic) Agents
3.4.2 Beta-2 Agonists
3.4.3 Nonselective Phosphodiesterase Inhibitors
3.4.4 Corticosteroids
3.4.5 Antibiotics
3.4.6 Mucous Regulators
3.4.7 Respiratory Support
3.4.8 Heliox (Helium-Oxygen) Therapy
3.4.9 Surgical Treatments
3.4.10 Alpha-1-Antitrypsin Replacement
3.5 Research and Development for COPD
3.5.1 Tiotropium (Spiriva)
3.5.2 Salmeterol
3.5.3 AD 237 and AD 313 (From Arakis)
3.5.4 ABX-IL8 Monoclonal Antibody
3.5.5 Roflumilast (PDE Inhibitor)
3.5.6 Other Biotech-based Compounds
3.6 World Market Size and Growth
3.6.1 Overall Global
3.6.2 United States
3.6.3 Western Europe
3.6.4 Japan
3.6.5 Rest of the World
3.7 Competitor Analysis
4 Asthma
4.1 Overview
4.2 Risk factors
4.3 Incidence and Mortality
4.4 Treatments for Asthma
4.4.1 Corticosteroids
4.4.2 Beta-2 Agonists
4.4.3 Leukotriene Modifiers
4.4.4 Anticholinergics
4.4.5 Theophylline
4.4.6 Cromolyn Sodium and Nedocromil
4.5 Research and Development for Asthma
4.6 World Market Size and Growth
4.6.1 Overall Global
4.6.2 United States
4.6.3 Western Europe
4.6.4 Japan
4.6.5 Rest of the World
4.7 Competitor Analysis
5 Cystic Fibrosis
5.1 Overview
5.2 Risk Factors
5.3 Incidence and Mortality
5.4 Treatments for Cystic Fibrosis
5.4.1 Anti-Inflammatory Agents
5.4.2 Antibiotics
5.4.3 Mucolytic Agents
5.4.4 Chest Therapy
5.4.5 Nutrition
5.4.6 Enzyme Replacement
5.4.7 Surgery
5.5 Research and Development for Cystic Fibrosis
5.5.1 Gene Therapies
5.5.2 Protein-Assist and Chloride Channel Therapies
5.5.3 Anti-Inflammatory Therapies
5.5.4 Anti-Infection Therapies
5.6 World Market Size and Growth
5.6.1 Overall Global
5.6.2 United States
5.6.3 Western Europe
5.6.4 Japan
5.6.5 Rest of the World
5.7 Competitor Analysis
6 Pulmonary Fibrosis
6.1 Overview
6.2 Risk Factors
6.3 Incidence and Mortality
6.4 Treatments for Pulmonary Fibrosis
6.4.1 Corticosteroids
6.4.2 Cytotoxic Drugs (Cyclophosphamide or Azathioprine)
6.4.3 Other Pharmacologic Agents
6.4.4 Non-Pharmacologic Therapies: Oxygen, Pulmonary Rehab, Surgery
6.5 Research and Development for Pulmonary Fibrosis
6.5.1 Agents Affecting Collagen Synthesis or Fibrosis
6.5.2 Antioxidants
6.5.3 Other Therapies in Development
6.6 World Market Size and Growth
6.6.1 Overall Global
6.6.2 United States
6.6.3 Western Europe
6.6.4 Japan
6.6.5 Rest of the World
7 Pulmonary Hypertension
7.1 Overview
7.2 Risk Factors
7.3 Incidence and Mortality
7.4 Treatments for Pulmonary Hypertension
7.4.1 Calcium Channel Blockers
7.4.2 Vasodilators
7.4.3 Endothelin Receptor Antagonists
7.4.4 Anticoagulation Agents
7.4.5 Cardiac Glycosides
7.4.6 Diuretics
7.4.7 Supportive Oxygen Therapy
7.4.8 Surgical Intervention
7.4.9 Dietary Therapy
7.5 Research and Development for Pulmonary Hypertension
7.5.1 Non-Intravenous Prostacyclin Analogs
7.5.2 Genes Under Study
7.5.3 Sildenafil Citrate (Viagra)
7.6 World Market Size and Growth
7.6.1 Overall Global
7.6.2 United States
7.6.3 Western Europe
7.6.4 Japan
7.6.5 Rest of the World
7.7 Competitor Analysis
8 Pulmonary Embolism
8.1 Overview
8.2 Risk Factors
8.3 Incidence and Mortality
8.4 Treatments for Pulmonary Embolism
8.4.1 Fibrinolytic Therapy
8.4.2 Anticoagulant Therapy
8.4.3 Surgery
8.4.4 Compression Stockings
8.4.5 Pulmonary Embolism Prevention
8.5 Research and Development for Pulmonary Embolism
8.6 World Market Size and Growth
8.6.1 Overall Global
8.6.2 United States
8.6.3 Western Europe
8.6.4 Japan
8.6.5 Rest of the World
8.7 Competitive Analysis
9 Pulmonary Sarcoidosis
9.1 Overview
9.2 Risk Factors
9.3 Incidence and Mortality
9.4 Treatments for Pulmonary Sarcoidosis
9.4.1 Corticosteroid
9.4.2 Cytotoxic Agents
9.4.3 Antimalarial Agents
9.4.4 Cyclosporin
9.4.5 Non-Pharmacologic Therapies
9.5 Research and Development for Pulmonary Sarcoidosis
9.5.1 TNF Inhibitors
9.6 World Market Size and Growth
9.6.1 Overall Global
9.6.2 United States
9.6.3 Western Europe
9.6.4 Japan
9.6.5 Rest of the World
9.7 Competitive Analysis
10 Bronchopulmonary Dysplasia
10.1 Overview
10.2 Risk Factors
10.3 Incidence and Mortality
10.4 Treatments for BPD
10.5 Research and Development for BPD
10.6 World Market Size and Growth
10.6.1 Overall Global
10.6.2 United States
10.6.3 Western Europe
10.6.4 Japan
10.6.5 Rest of the World
11 Respiratory Distress Syndrome
11.1 Overview
11.2 Risk Factors
11.3 Incidence and Mortality
11.4 Treatments for Respiratory Distress Syndrome
11.5 Research and Development for Respiratory Distress Syndrome
11.6 World Market Size and Growth
11.6.1 Overall Global
11.6.2 United States
11.6.3 Western Europe
11.6.4 Japan
11.6.5 Rest of the World
11.7 Competitive Analysis
12 Company Profiles
12.1 3M Pharmaceuticals
12.2 Aerogen, Inc.
12.3 Affinium Pharmaceuticals
12.4 Alkermes, Inc.
12.5 Alliance Pharmaceutical
12.6 Altana AG
12.7 Aradigm Corp.
12.8 AstraZeneca Pharmaceuticals
12.9 Aurora Biosciences
12.10 Avanir Pharmaceuticals
12.11 Aventis Pharmaceuticals
12.12 Bayer
12.13 BioXell
12.14 Boehringer Ingelheim
12.15 Bristol-Myers Squibb
12.16 Celera Genomics
12.17 deCODE genetics
12.18 Demegen
12.19 Discovery Laboratories
12.20 Dyax Corp.
12.21 Elan Corp.
12.22 EpiGenesis Pharmaceuticals
12.23 Exhale Therapeutics, Inc.
12.24 Genaera Corp.
12.25 Genentech
12.26 GlaxoSmithKline
12.27 GLYCODesign Inc.
12.28 Hoffmann-La Roche
12.29 ICOS Corp.
12.30 IDEC Pharmaceuticals
12.31 Inflazyme Pharmaceuticals
12.32 Inhale Therapeutic Systems
12.33 Inspire Pharmaceuticals
12.34 InterMune Pharmaceuticals
12.35 IVAX Corp.
12.36 Martek Biosciences
12.37 MedImmune, Inc.
12.38 Merck & Co., Inc.
12.39 Millennium Pharmaceuticals, Inc.
12.40 MoliChem Medicines
12.41 Novartis Pharmaceuticals
12.42 Peptech
12.43 Pharmacia Corp.
12.44 Protein Design Labs, Inc.
12.45 PPL Therapeutics
12.46 Rigel Pharmaceuticals
12.47 Schering-Plough
12.48 SciClone Pharmaceuticals
12.49 Sepracor Inc.
12.50 Sheffield Pharmaceuticals
12.51 Structural GenomiX
12.52 Tanox Biosystems
12.53 Targeted Genetics
12.54 Texas Biotechnology
12.55 Transave, Inc.
12.56 Vectura Ltd.
12.57 ViroPharma Inc.
13 Company Directory
14 References
14.1 References for Introduction Chapter
14.2 References for COPD Chapter
14.3 References for Asthma Chapter
14.4 References for Cystic Fibrosis Chapter
14.5 References for Pulmonary Fibrosis Chapter
14.6 References for Pulmonary Hypertension Chapter
14.7 References for Pulmonary Embolism Chapter
14.8 References for Pulmonary Sarcoidosis Chapter
14.9 References for Bronchopulmonary Dysplasia Chapter
14.10 References for Respiratory Distress Syndrome Chapter
List of Tables
- Table 1-1 Total World Market Size Projection of Pulmonary/Lung Disease Therapeutics 2002, 2007
- Table 1-2 World Pulmonary/Lung Disease Therapeutic Market Shares by Disease Type 2002, 2007
- Table 2-1 Deaths From Pulmonary Disease in the U.S. (Excluding Cancer) Percent by Subgroup 1999
- Table 3-1 Total World COPD Drug Market Size Projection 2002, 2007
- Table 3-2 COPD Drug Market Size Projection by Geographic Region 2002, 2007
- Table 3-3 Geographic Market Shares of COPD Drugs 2002
- Table 3-4 Geographic Market Shares of COPD Drugs 2007
- Table 4-1 Total World Asthma Drug Market Size Projection 2002, 2007
- Table 4-2 Asthma Drug Market Size Projection by Geographic Region 2002, 2007
- Table 4-3 Geographic Market Shares of Asthma Drugs 2002
- Table 4-4 Geographic Market Shares of Asthma Drugs 2007
- Table 4-5 World Asthma Drug Market Share by Drug Class 2002
- Table 5-1 Total World Cystic Fibrosis Drug Market Size Projection 2002, 2007
- Table 5-2 Cystic Fibrosis Drug Market Size Projection by Geographic Region 2002, 2007
- Table 5-3 Geographic Market Shares of Cystic Fibrosis Drugs 2002
- Table 5-4 Geographic Market Shares of Cystic Fibrosis Drugs 2007
- Table 5-5 Cystic Fibrosis Foundation Research Grants, 5 Largest by Company
- Table 6-1 Total World Pulmonary Fibrosis Drug Market Size Projection 2002, 2007
- Table 6-2 Pulmonary Fibrosis Drug Market Size Projection by Geographic Region 2002, 2007
- Table 6-3 Geographic Market Shares of Pulmonary Fibrosis Drugs 2002
- Table 6-4 Geographic Market Shares of Pulmonary Fibrosis Drugs 2007
- Table 7-1 Total World Pulmonary Hypertension Drug Market Size Projection 2002, 2007
- Table 7-2 Pulmonary Hypertension Drug Market Size Projection by Geographic Region 2002, 2007
- Table 7-3 Geographic Market Shares of Pulmonary Hypertension Drugs 2002
- Table 7-4 Geographic Market Shares of Pulmonary Hypertension Drugs 2007
- Table 8-1 Total World Pulmonary Embolism Drug Market Size Projection 2002, 2007
- Table 8-2 Pulmonary Embolism Drug Market Size Projection by Geographic Region 2002, 2007
- Table 8-3 Geographic Market Shares of Pulmonary Embolism Drugs 2002
- Table 8-4 Geographic Market Shares of Pulmonary Embolism Drugs 2007
- Table 9-1 Total World Pulmonary Sarcoidosis Drug Market Size Projection 2002, 2007
- Table 9-2 Pulmonary Sarcoidosis Drug Market Size Projection by Geographic Region 2002, 2007
- Table 9-3 Geographic Market Shares of Pulmonary Sarcoidosis Drugs 2002
- Table 9-4 Geographic Market Shares of Pulmonary Sarcoidosis Drugs 2007
- Table 10-1 Total World Bronchopulmonary Dysplasia Drug Market Size Projection 2002, 2007
- Table 10-2 Bronchopulmonary Dysplasia Drug Market Size Projection by Geographic Region
2002, 2007
- Table 10-3 Geographic Market Shares of Bronchopulmonary Dysplasia Drugs 2002
- Table 10-4 Geographic Market Shares of Bronchopulmonary Dysplasia Drugs 2007
- Table 11-1 Total World Respiratory Distress Syndrome Drug Market Size Projection 2002, 2007
- Table 11-2 Respiratory Distress Syndrome Drug Market Size Projection by Geographic Region 2002, 2007
- Table 11-3 Geographic Market Shares of Respiratory Distress Syndrome Drugs 2002
- Table 11-4 Geographic Market Shares of Respiratory Distress Syndrome Drugs 2007
- Table 12-1 Company Market Involvement by Pulmonary Disease Area
List of Figures
- Figure 1-1 Total World Market Size Projection of Pulmonary/Lung Disease Therapeutics 2002, 2007
- Figure 3-1 Total World COPD Drug Market Size Projection 2002, 200
- Figure 3-2 COPD Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 3-3 Geographic Market Shares of COPD Drugs 2002
- Figure 3-4 Geographic Market Shares of COPD Drugs 2007
- Figure 3-5 COPD Drug Market Size Projection in U.S. 2002, 2007
- Figure 3-6 COPD Drug Market Size Projection in Western Europe 2002, 2007
- Figure 3-7 COPD Drug Market Size Projection in Japan 2002, 2007
- Figure 3-8 COPD Drug Market Size Projection in Rest of World 2002, 2007
- Figure 4-1 Total World Asthma Drug Market Size Projection 2002, 2007
- Figure 4-2 Asthma Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 4-3 Geographic Market Shares of Asthma Drugs 2002
- Figure 4-4 Geographic Market Shares of Asthma Drugs 2007
- Figure 4-5 World Asthma Drug Market Share by Drug Class 2002
- Figure 4-6 Asthma Drug Market Size Projection in U.S. 2002, 2007
- Figure 4-7 Asthma Drug Market Size Projection in Western Europe 2002, 2007
- Figure 4-8 Asthma Drug Market Size Projection in Japan 2002, 2007
- Figure 4-9 Asthma Drug Market Size Projection in Rest of World 2002, 2007
- Figure 5-1 Total World Cystic Fibrosis Drug Market Size Projection 2002, 2007
- Figure 5-2 Cystic Fibrosis Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 5-3 Geographic Market Shares of Cystic Fibrosis Drugs 2002
- Figure 5-4 Geographic Market Shares of Cystic Fibrosis Drugs 2007
- Figure 5-5 Cystic Fibrosis Drug Market Size Projection in U.S. 2002, 2007
- Figure 5-6 Cystic Fibrosis Drug Market Size Projection in Western Europe 2002, 2007
- Figure 5-7 Cystic Fibrosis Drug Market Size Projection in Japan 2002, 2007
- Figure 5-8 Cystic Fibrosis Drug Market Size Projection in Rest of World 2002, 2007
- Figure 6-1 Total World Pulmonary Fibrosis Drug Market Size Projection 2002, 2007
- Figure 6-2 Pulmonary Fibrosis Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 6-3 Geographic Market Shares of Pulmonary Fibrosis Drugs 2002
- Figure 6-4 Geographic Market Shares of Pulmonary Fibrosis Drugs 2007
- Figure 6-5 Pulmonary Fibrosis Drug Market Size Projection in U.S. 2002, 2007
- Figure 6-6 Pulmonary Fibrosis Drug Market Size Projection in Western Europe 2002, 2007
- Figure 6-7 Pulmonary Fibrosis Drug Market Size Projection in Japan 2002, 2007
- Figure 6-8 Pulmonary Fibrosis Drug Market Size Projection in Rest of World 2002, 2007
- Figure 7-1 Total World Pulmonary Hypertension Drug Market Size Projection 2002, 2007
- Figure 7-2 Pulmonary Hypertension Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 7-3 Geographic Market Shares of Pulmonary Hypertension Drugs 2002
- Figure 7-4 Geographic Market Shares of Pulmonary Hypertension Drugs 2007
- Figure 7-5 Pulmonary Hypertension Drug Market Size Projection in U.S. 2002, 2007
- Figure 7-6 Pulmonary Hypertension Drug Market Size Projection in Western Europe 2002, 2007
- Figure 7-7 Pulmonary Hypertension Drug Market Size Projection in Japan 2002, 2007
- Figure 7-8 Pulmonary Hypertension Drug Market Size Projection in Rest of World 2002, 2007
- Figure 8-1 Total World Pulmonary Embolism Drug Market Size Projection 2002, 2007
- Figure 8-2 Pulmonary Embolism Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 8-3 Geographic Market Shares of Pulmonary Embolism Drugs 2002
- Figure 8-4 Geographic Market Shares of Pulmonary Embolism Drugs 2007
- Figure 8-5 Pulmonary Embolism Drug Market Size Projection in U.S. 2002, 2007
- Figure 8-6 Pulmonary Embolism Drug Market Size Projection in Western Europe 2002, 2007
- Figure 8-7 Pulmonary Embolism Drug Market Size Projection in Japan 2002, 2007
- Figure 8-8 Pulmonary Embolism Drug Market Size Projection in Rest of World 2002, 2007
- Figure 9-1 Total World Pulmonary Sarcoidosis Drug Market Size Projection 2002, 2007
- Figure 9-2 Pulmonary Sarcoidosis Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 9-3 Geographic Market Shares of Pulmonary Sarcoidosis Drugs 2002
- Figure 9-4 Geographic Market Shares of Pulmonary Sarcoidosis Drugs 2007
- Figure 9-5 Pulmonary Sarcoidosis Drug Market Size Projection in U.S. 2002, 2007
- Figure 9-6 Pulmonary Sarcoidosis Drug Market Size Projection in Western Europe 2002, 2007
- Figure 9-7 Pulmonary Sarcoidosis Drug Market Size Projection in Japan 2002, 2007
- Figure 9-8 Pulmonary Sarcoidosis Drug Market Size Projection in Rest of World 2002, 2007
- Figure 10-1 Total World Bronchopulmonary Dysplasia Drug Market Size Projection 2002, 2007
- Figure 10-2 Bronchopulmonary Dysplasia Drug Market Size Projection by Geographic Region
2002, 2007
- Figure 10-3 Geographic Market Shares of Bronchopulmonary Dysplasia Drugs 2002
- Figure 10-4 Geographic Market Shares of Bronchopulmonary Dysplasia Drugs 2007
- Figure 10-5 Bronchopulmonary Dysplasia Drug Market Size Projection in U.S. 2002, 2007
- Figure 10-6 Bronchopulmonary Dysplasia Drug Market Size Projection in Western Europe 2002, 2007
- Figure 10-7 Bronchopulmonary Dysplasia Drug Market Size Projection in Japan 2002, 2007
- Figure 10-8 Bronchopulmonary Dysplasia Drug Market Size Projection in Rest of World 2002, 2007
- Figure 11-1 Total World Respiratory Distress Syndrome Drug Market Size Projection 2002, 2007
- Figure 11-2 Respiratory Distress Syndrome Drug Market Size Projection by Geographic Region 2002, 2007
- Figure 11-3 Geographic Market Shares of Respiratory Distress Syndrome Drugs 2002
- Figure 11-4 Geographic Market Shares of Respiratory Distress Syndrome Drugs 2007
- Figure 11-5 Respiratory Distress Syndrome Drug Market Size Projection in U.S. 2002, 2007
- Figure 11-6 Respiratory Distress Syndrome Drug Market Size Projection in Western Europe 2002, 2007
- Figure 11-7 Respiratory Distress Syndrome Drug Market Size Projection in Japan 2002, 2007
- Figure 11-8 Respiratory Distress Syndrome Drug Market Size Projection in Rest of World 2002, 2007
AbstractPulmonary disease covers a wide range of disorders, from relatively benign conditions such as cough, cold, and allergy to potentially life-threatening conditions such as asthma and chronic obstructive pulmonary disease (COPD). In the U.S., lung disease is ranked as the fourth-leading cause of death (after heart disease, cancer, and stroke) and is responsible for approximately 1 in 7 deaths. However, while the death rates for heart disease and cancer are in decline, the death rate for lung disease is increasing.
This report provides analyses of the U.S. and world markets for drug therapeutics to treat pulmonary/lung diseases and disorders. The total worldwide market for therapeutics to treat the following specified pulmonary diseases is estimated to reach $17 billion in 2002:
- COPD
- Asthma
- Cystic fibrosis
- Pulmonary fibrosis
- Pulmonary hypertension
- Pulmonary embolism
- Pulmonary sarcoidosis
- Bronchopulmonary dysplasia
- Respiratory distress syndrome
The report focuses on pulmonary disease therapies worldwide and includes an analysis of future developments in the treatment of respective conditions. Global regional market size projections (in U.S. dollars) and shares are covered, as well as discussion of market competitors and products.
Please Note: Theta requires that, for PDF orders, clients sign a confidentiality agreement prior to fulfillment of PDF email delivery.
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
